Where does Ipca Laboratories make most of its revenue?

outside India: 55% of revenue by region in fiscal year 2025, followed by India (45%).

What companies are similar to Ipca Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Alkem Laboratories Limited (ALKEM.NS), Biocon Limited (BIOCON.NS), Abbott India Limited (ABBOTINDIA.NS), GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS).

Ipca Laboratories Limited (IPCALAB.NS) Stock

About Ipca Laboratories Limited

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including al...

At a glance

In Q2 2026 (the quarter ended September 30, 2025) revenue was 25.57 billion INR, up 8.6% from a year before. outside India was its largest region in fiscal year 2025, with 55% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.